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Background: Sevoflurane potently enhances glycine receptor currents and more modestly decreases NMDA
receptor currents, each of which may contribute to immobility. This modest NMDA receptor antagonism by
sevoflurane at a minimum alveolar concentration (MAC) could be reciprocally related to large potentiation of other
inhibitory ion channels. If so, then reduced glycine receptor potency should increase NMDA receptor antagonism
by sevoflurane at MAC.
Methods: Indwelling lumbar subarachnoid catheters were surgically placed in 14 anesthetized rats. Rats were
anesthetized with sevoflurane the next day, and a pre-infusion sevoflurane MAC was measured in duplicate using a
tail clamp method. Artificial CSF (aCSF) containing either 0 or 4 mg/mL strychnine was then infused intrathecally at
4 μL/min, and the post-infusion baseline sevoflurane MAC was measured. Finally, aCSF containing strychnine (either
0 or 4 mg/mL) plus 0.4 mg/mL dizocilpine (MK-801) was administered intrathecally at 4 μL/min, and the post-
dizocilpine sevoflurane MAC was measured.
Results: Pre-infusion sevoflurane MAC was 2.26%. Intrathecal aCSF alone did not affect MAC, but intrathecal
strychnine significantly increased sevoflurane requirement. Addition of dizocilpine significantly decreased MAC in all
rats, but this decrease was two times larger in rats without intrathecal strychnine compared to rats with intrathecal
strychnine, a statistically significant (P< 0.005) difference that is consistent with increased NMDA receptor
antagonism by sevoflurane in rats receiving strychnine.
Conclusions: Glycine receptor antagonism increases NMDA receptor antagonism by sevoflurane at MAC. The
magnitude of anesthetic effects on a given ion channel may therefore depend on the magnitude of its effects on
other receptors that modulate neuronal excitability.Background
Several ion channels and cell receptors have been identi-
fied as possible targets responsible for the mechanism of
inhaled anesthetic action; among these are 3-transmem-
brane (3TM) receptors, such as N-methyl-d-aspartate
(NMDA) receptors, and 4-transmembrane (4TM) recep-
tors, such as γ-aminobutyric acid (GABA) receptors and
glycine receptors. At a minimum alveolar concentration
(MAC), the magnitude of receptor potentiation or inhib-
ition by a given anesthetic agent differs greatly between
receptor types [1,2], implying that the respective contri-
butions of these receptors to anesthetic endpoints such
as immobility and amnesia likewise differs. Many inhaled
agents show an inverse relationship between efficacy at* Correspondence: rjbrosnan@ucdavis.edu
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and reproduction in any medium, provided the3TM and 4TM receptors. For example, cyclopropane
and benzene cause >50% NMDA receptor inhibition at
MAC, but only potentiate GABAA receptors by <50% at
this same concentration. In contrast, halothane and iso-
flurane potentiate GABA receptors by >350% at MAC
while inhibiting NMDA receptors by <30% [1,2].
It is unclear precisely how inhaled anesthetics cause
general anesthesia [3]. One possible explanation is that
the volatile anesthetics act through multiple receptor
targets to inhibit excitatory ion channels and potenti-
ate inhibitory ion channels; the combination of these
effects within the spinal cord reduces neuronal excit-
ability to the point of causing immobility at anesthetic
concentrations equal to or greater than MAC [4]. If
anesthesia results from a summation of ion channel
effects in critical neurons, then greater anesthetic po-
tency and efficacy in some receptor types may offsetd Central Ltd. This is an Open Access article distributed under the terms of the
reativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution,
original work is properly cited.
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to anesthesia.
Haloethers, such as isoflurane, sevoflurane, and des-
flurane, potentiate glycine and GABAA receptors much
more than they inhibit NMDA receptors at MAC [5-7].
To the extent that both receptor classes are relevant to
anesthetic action, we postulate that the haloethers
weakly modulate NMDA receptors at MAC for the rea-
son that they more efficaciously and potently modulate
other receptor targets such as GABA and glycine recep-
tors. Conversely, a decrease in efficacy or potency at
other important receptor targets may necessitate
increased contributions from NMDA receptors to reach
the same immobilizing anesthetic endpoint. For ex-
ample, when the GABAA antagonist picrotoxin is admi-
nistered intrathecally to decrease isoflurane potency and
efficacy at the GABAA receptor, isoflurane binds a
greater fraction of NMDA receptors at MAC suggesting
that there is greater contribution from this receptor to
immobility produced by isoflurane [4].
However, would altering potency of a different ether
anesthetic via a different molecular mechanism yield a
similar increase in NMDA receptor antagonism at
MAC? To answer this question, sevoflurane MAC will
be measured in rats during intrathecal administration of
either aCSF controls or aCSF + strychnine, a glycine re-
ceptor antagonist. Because strychnine will increase sevo-
flurane MAC and since sevoflurane dose-dependently
inhibits NMDA receptors, there should be increased
NMDA receptor binding at increased sevoflurane MAC.
Next, dizocilpine (MK801), an NMDA receptor antagon-
ist, will be added to the intrathecal infusion and subse-
quently decrease MAC. Since the strychnine rats should
have a greater fraction of NMDA receptors already
bound and inhibited by sevoflurane, dizocilpine should
decrease MAC less in these animals compared to con-
trols. Such a finding would be consistent with an
increased role for NMDA receptors in the anesthetic
mechanism of action for sevoflurane at an increased
MAC.
Methods
Fourteen male Sprague–Dawley rats (Harlan, Livermore,
CA) aged 72 ± 3 days and weighing 277 ± 18 g (mean ±
SD) were studied. Animals were housed individually
with a 12 hour light/dark cycle and with food and water
available ad libitum. The University of California Davis
IACUC approved this research protocol.
Interthecal Catheter Placement
Sevoflurane (SevoFlo, Abbot Laboratories, Abbot Park,
IL) was used to induce anesthesia in rats within an
acrylic chamber. Anesthesia was maintained with sevo-
flurane in oxygen delivered by facemask and a MaplesonE circuit. The technique used for surgical placement of
the intrathecal catheter has been described in detail [4].
Briefly, rats were positioned within a stereotaxic frame
with cervical ventroflexion, and the head and neck were
shaved, aseptically prepared, and draped. The skin from
the parietal bone to the distal spinous process of the axis
was incised, and blunt dissection was used to divide and
retract the epaxial muscles between the midline facial
planes. A 0.5 mm incision was made through the
exposed dorsal atlantooccipital membrane through
which a 32-gauge intrathecal catheter (Part 0046,
RecathCo, Allison Park, PA) was advanced to the mid-
lumbar vertebral region. The catheter neck was adhered
to deep tissue planes with a drop of cyanoacrylate glue,
the exposed catheter lumen was plugged with a 0.35 mm
diameter stainless steel wire, and muscles and skin were
sutured closed in separate layers.
The incision was infiltrated with 0.15 mL of 1% lido-
caine, and 0.5 mg flunixin meglumine was administered
IM for analgesia. Rats recovered from anesthesia with
facemask oxygen, and heating blankets were used to cor-
rect hypothermia. Once awake and moving, rats were
returned to their cages; all animals were eating or drink-
ing within 1 hour of recovery and no motor deficits were
evident in any animal. Rats were allowed an additional
36–48 hour recovery period prior to the sevoflurane
MAC studies.
Intrathecal solution preparation
Animals were assigned to either a control group or the
strychnine group, and each experiment was conducted
in the following sequence: Baseline MAC measurement
(no intrathecal solution administered), Pre-dizocilpine
MAC measurement (strychnine or control intrathecal
solution administered), and Dizocilpine MAC measure-
ment (strychnine + dizocilpine or control + dizocilpine).
Study solutions were prepared daily using artificial
cerebrospinal fluid (aCSF) perfusion fluid (Harvard Ap-
paratus, Holliston, MA) and sterile syringes. For the Pre-
dizocilpine measurements, a solution of 4 mg/mL L-
strychnine (98%, Acros Organics, Geel, Belgium) was
prepared in aCSF within a 10 mL additive-free, stop-
pered blood collection tube. In order to solubilize
strychnine at this concentration, a 10 ml syringe and
needle were used to create a vacuum within the tube,
and the headspace was replaced with 99.99% CO2
(Matheson, Newark, CA). This process was repeated for
a total of 10 headspace exchanges and resulted in ap-
proximately 1 atm CO2 tension. The control pre-dizocil-
pine solution containing aCSF alone was similarly
acidified with CO2 headspace exchanges and measured
using the same gas analyzer.
The solutions for the dizocilpine measurements were
prepared under sterile conditions in a manner identical
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cept for the addition of 0.4 mg/mL (+)-MK801 hydrogen
maleate (dizocilpine, Sigma, St. Louis, MO) in both the
strychnine and control solutions. Finally, all dizocilpine
solutions were acidified with CO2 to 1 atm pressure.
MAC measurement
Rats were individually anesthetized with sevoflurane/O2
in 8 × 30 cm acrylic cylinders that were connected in
parallel to the fresh gas supply. The inlet was sealed
using a one-holed rubber stopper for delivery of oxygen
and sevoflurane at a rate of ≥1 L/min per cylinder; a luer
adapter allowed a short, stopcock-sealed polypropylene
coaxial tube to be used for chamber gas sampling near
the nose of the anesthetized rat. The outlet of each cy-
linder was sealed using a two- holed stopper; rat tails
were inserted through one hole until occluded, and a
passive waste gas scavenging system was attached to the
second hole. A thermistor probe (400 series, YSI, Yellow
Springs, OH) that was calibrated against a certified mer-
cury thermometer (SRM934-FC, ERTCO, Dubuque, IA)
also traversed a sealed portion of the distal stopcock in
order to measure rectal temperature which was main-
tained between 37 and 38°C using heating pads as
needed.
Once each rat was immobilized in its chamber and
instrumented with a temperature probe, 3 mL of 0.9%
saline was administered subcutaneously to each rat. The
delivered sevoflurane concentration was then changed to
2.2-2.5% and maintained constant for 20 min. After
equilibration, an alligator clamp was applied to the distal
tail and rotated back and forth for 60 sec. The chamber
gas was then sampled for analysis by gas chromatog-
raphy, and the presence or absence of movement in re-
sponse to tail clamp was recorded. If movement was
observed, the sevoflurane concentration was increased
by 10-15%. If no movement was observed, the sevoflur-
ane concentration was decreased by 10-15%. After
20 min equilibration at the new sevoflurane concentra-
tion, movement in response to tail clamping was re-
assessed at a site immediately proximal to the previous
test, cylinder gas was sampled for analysis, and the sevo-
flurane concentration was adjusted up-or-down accord-
ingly. MAC was defined as the arithmetic mean between
the highest sevoflurane concentration that permitted
movement and the proximate lowest sevoflurane con-
centration the prevented movement in response to tail
clamping. Baseline sevoflurane MAC for each rat
equaled the mean of duplicate MAC measurements
prior to intrathecal infusions.
Syringes containing pre-dizocilpine solution (either
control or strychnine, Table 1) were used to prime
extensions sets and blunt needles which were connected
to the intrathecal catheters, and the Pre-dizocilpinesolution was administered at 4 μL/min via a syringe
pump (PHD2000, Harvard Apparatus, Holliston, MA). A
3 mL volume of 0.9% NaCL was also again administered
subcutaneously to replace insensible and urinary fluid
losses. After a 60 min equilibration time with constant
pre-dizocilpine infusion and anesthetic dose, the sevo-
flurane MAC was re-measured in duplicate using the
same tail clamp bracketing technique described for the
baseline sevoflurane MAC measurements. All strychnine
infusions caused spontaneous and intermittent muscle
fasciculation and myoclonus even during apparently
deep planes of sevoflurane anesthesia; however only
movement that occurred in response to noxious stimula-
tion was considered a positive response endpoint for a
MAC bracket [8].
Next, syringes with primed fluid lines and needles con-
taining the dizocilpine solution (either control or strych-
nine) were connected to the intrathecal catheters. The
dizocilpine solution was again administered at 4 μL/min,
and an additional 3 mL of 0.9% saline was administered
subcutaneously. After 60 min requilibration time with
the dizocilpine infusion and new sevoflurane dose, MAC
was re-measured in duplicate using the same bracketing
tail clamp technique for the baseline and pre-dizocilpine
MAC determinations. All rats were euthanized at the
end of the study. The mean total anesthetic time for
each experiment was 7.2 hours.
Gas concentration measurement
Chamber gas concentrations were monitored continu-
ously using a multi-agent infrared anesthetic gas and
paramagnetic oxygen analyzer (Andros Model 4800,
LumiSense, Orange, CA). For MAC measurements, cy-
linder gas samples were collected in a glass syringe and
analyzed using a gas chromatograph (Clarus 500, Perkin
Elmer, Waltham, MA) with direct injection by a 0.25 mL
sample loop onto a 183 cm long and 0.32 cm diameter
packed SF-96 column at 100°C, a flame ionization de-
tector at 150°C, and ultra-zero air, H2 and He flow rates
of 350, 35, and 20 mL/min, respectively. The resulting
sevoflurane peak had a retention time of 1.23 min, and
the area under the curve was integrated using commer-
cial software (TotalChrom, Perkin Elmer, Waltham,
MA). The chromatograph was calibrated using second-
ary sevoflurane gas standards having concentrations pre-
viously determined by calibration against multiple
primary sevoflurane gas standards that were prepared
using the Ideal Gas Law.
Statistical analysis
Data were described as mean ± SD, and normal distribu-
tions of data were verified by visual inspection of normal
probability plots and by Shapiro-Wilk tests. Planned
contrasts between control and strychnine groups among
Table 1 Intathecal drugs administered to “control” and “strychnine” rat treatment groups during baseline,
pre-dizocilpine, and dizocilpine MAC measurement periods
Group Baseline Pre-Dizocilpine Dizocilpine
Control no infusion aCSF+CO2 aCSF +CO2 + dizocilpine
Strychnine no infusion aCSF+CO2 + strychnine aCSF + CO2 + strychnine +dizocilpine
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were analyzed using Student t-tests with Dunn-Sidak
corrections for multiple comparisons (v.11, SPSS, Chi-
cago, IL). A P< 0.05 indicated statistical significance.Results
Sevoflurane MAC in rats prior to intrathecal infusions
was 2.26 ± 0.21%atm (mean ± SD). Animals were
anesthetized and studied for an average of 7.2 ± 1.8
hours, and duplicate MAC measurements were similar
within treatments. The percent change from the first to
second sevoflurane MAC measurements, expressed as
100  MAC2MAC2MAC1 for control and strychnine treatments,
respectively, was: 0.3 ± 0.4 and 0.5 ± 1.6% before aCSF
infusions, 1.2 ± 1.1 and 5.1 ± 17.7% during the aCSF infu-
sions without dizocilpine, and −5.5 ± 18.5 and 0.2 ± 3.8%
during the aCSF infusions with dizocilpine.
Intrathecal strychnine increased sevoflurane MAC by
56% compared to control rats receiving only acidified
aCSF (Figure 1). Administration of acidified aCSF alone
had essentially no effect on anesthetic requirement; the
control sevoflurane MAC during aCSF-infusion was un-
changed from the control sevoflurane MAC pre-infusion
(Figure 1).Within 10 minutes of administration, strych-
nine produced intermittent myoclonus in all animals un-
related to noxious stimulation. However, seizure-like
activity appeared to decrease or cease following additionFigure 1 Sevoflurane MAC before and after intrathecal
administration of CO2-acidified aCSF either without (control) or
with 4 mg/mL strychnine. Statistically significant differences
are indicated by an asterisk (*). MAC was unchanged in control
animals, indicating that neither intrathecal administration of aCSF
nor CO2 significantly altered sevoflurane requirement. In contrast,
intrathecal strychnine significantly increased sevoflurane MAC.of the NMDA antagonist dizocilpine (MK801) to the
intrathecal strychnine infusion. Dizocilpine also
decreased sevoflurane MAC in both the control and
strychnine treatment groups, though MAC in the strych-
nine group remained significantly greater than for the
control group (Figure 2). However, the magnitude of the
dizocilpine MAC-sparing effect was significantly differ-
ent between groups. In the control group, dizocilpine
reduced the mean sevoflurane MAC from 2.15 ± 0.38%
atm to 1.14 ± 0.46%atm, a change of 1.01 ± 0.17%atm
sevoflurane. In the strychnine group, dizocilpine reduced
the mean sevoflurane MAC from 3.36 ± 0.17%atm to
2.85 ± 0.33%atm, a difference of only 0.49 ± 0.31%atm
sevoflurane. Hence, when sevoflurane MAC was
increased using strychnine, the dizocilpine MAC-sparing
effect was halved.Discussion
Intrathecal strychnine increased sevoflurane MAC by
56%. Sevoflurane, like other haloether anesthetics, causes
concentration-dependent NMDA receptor inhibition,
and the MAC change observed in the present in vivo
study corresponds to a 10-15% increase in NMDA re-
ceptor inhibition based on in vitro electrophysiologic
studies [9]. Greater NMDA receptor inhibition at
increased sevoflurane MAC reduces the population of
NMDA receptors available for binding and modulationFigure 2 Sevoflurane MAC during intrathecal administration of
CO2-acidified aCSF (MAC-aCSF) and during administration
of acidified aCSF containing 0.4 mg/mL dizocilpine
(MAC-dizocilpine), either without (control) or with 4 mg/mL
strychnine. The strychnine MAC values were both significantly
greater than their corresponding control sevoflurane MAC values
(* P< 0.05) The difference in sevoflurane MAC before and after
dizocilpine administration is shown in the far right bars for both
control (C) and strychnine (S) rats.
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pine [7]. As a result, dizocilpine efficacy should be
diminished during administration of high sevoflurane
concentrations. In fact, this is what we observed in
the present study, and it is consistent with increased
sevoflurane NMDA receptor antagonism in rats when
sevoflurane MAC is increased as a result of glycine
receptor antagonism.
Sevoflurane and other ether anesthetics exhibit
greater glycine receptor potentiation [5,6] than NMDA
receptor inhibition [7,9] at an anesthetic EC50 or
MAC. However, this does not generally appear to be a
fixed property of the ether anesthetics. If inhaled
anesthetic immobility is a summation of systemic
effects produced by negative modulation of one or
more excitatory cell receptors and positive modulation
by one or more inhibitory cell receptors [3], then high
efficacy at one relevant higher affinity receptor site
might render unnecessary the contributions from other
potentially relevant lower-affinity sites. The ether
anesthetics at MAC may exhibit lower efficacy for
some 3-transmembrane receptors, such as NMDA
receptors, because immobility may arise primarily
through actions at 4-transmembrane receptors, such
as GABAA and glycine receptors [10], among other
putatively relevant targets [3]. A decrease in haloether
potency at 4-transmembrane sites—whether by admin-
istration of glycine antagonists during sevoflurane
anesthesia as reported here or by administration of a
GABAA antagonist during isoflurane anesthesia as
described in an analogous study [4] appears to aug-
ment the contribution of NMDA receptors (and pre-
sumably other relevant spinal targets) to mobility
during general anesthesia.
The spinal cord is the primary site for the immobiliz-
ing action of inhaled anesthetics [11]; hence receptor
antagonists in this study were administered intrathecally
rather than systemically. Although exhibiting a ceiling
effect [12], strychnine infusions at lower concentrations
around the spinal cord in rats dose-dependently increase
MAC in a manner that correlates with in vitro receptor
effects which suggests glycine receptors may contribute
to anesthetic immobility [13]. Sevoflurane dose-depend-
ently decreases NMDA-dependent depolarization of
nociceptive and non-nociceptive neurons within the rat
spinal cord [14] Likewise, dizocilpine dose-dependently
decreases MAC in rats to a greater magnitude during
spinal infusions compared to either intracerebroventri-
cular or intravenous infusions [15], suggesting that
NMDA antagonists are also relevant to the mechanism
of action of inhaled agents. Increased NMDA receptor
antagonism observed at increased sevoflurane MAC in
the present study would be consistent with increased
contribution of this receptor to immobility.Inferences regarding sevoflurane cellular actions have
been made with the assumption that pharmacologic ma-
nipulation of glycine and NMDA receptor function
occur independently of one another. Glycine does cause
positive allosteric modulation of NMDA receptors [16],
but these glycine binding sites are strychnine-insensitive
and therefore should not have been affected during
intrathecal strychnine infusions intended to increase
sevoflurane MAC. Morerover, neither glycine nor
GABAA receptor antagonists affect depression of inward
glutamate currents within the spinal cord caused by 1
MAC enfluran [17], and presumably by other ether anes-
thetics. Similarly, we are unaware of evidence for
enhanced spinal endogenous NMDA receptor inhibition
caused by spinal strychnine-sensitive glycine receptor
antagonism to controvert this assumption of
independence.
Sevoflurane MAC measured prior to intrathecal infu-
sions falls within the lower end of published values for
Sprague–Dawley rats [18,19]. Intrathecal strychnine
prior to dizocilpine administration increased MAC of
sevoflurane by 56%, but strychnine infusions maximally
increase isoflurane MAC by only 43% [12]. Agent differ-
ences are not explained by either receptor affinity or effi-
cacy for the glycine receptor, since the aqueous EC50 is
lower and the effect maximum is higher with isoflurane
versus sevoflurane for their respective logarithm dose–
response curves [6]. In contrast, dizocilpine in sevoflur-
ane-anesthetized control rats from the present study pro-
duced quantitatively similar MAC-sparing effects when
administered intrathecally to isoflurane-anesthetized rats
[15].
Strychnine is only sparingly soluble in water at physio-
logic pH and room temperature [20]. As a Lewis base,
strychnine solubility was increased through aCSF acidifi-
cation with CO2. Yet this posed another potential prob-
lem. Carbon dioxide is itself an anesthetic in rats, and it
dose-dependently decreases MAC of other anesthetics
[21]. Furthermore, CO2 negatively modulates NMDA
receptors [22] via noncompetitive and mixed inhibition
at the glutamate and glycine binding sites, respectively
[23]. But unlike hydronium ions, CO2 moves readily
across cell membranes, and a high local transdural par-
tial pressure gradient facilitates CO2 diffusion from the
CSF to the blood from which it is eliminated via alveolar
minute ventilation. This would explain why sevoflurane
MAC in control rats receiving intrathecal CO2-acidified
aCSF was unchanged from the pre-infusion measure-
ments in the same animals (Figure 1). It also suggests
that CO2 in these experiments was likely not a con-
founding factor with respect to NMDA receptor
function.
Nevertheless, there were important limitations to our
study design. Although a control group was used for
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ment (aCSF with versus without strychnine) which po-
tentially could have introduced bias in MAC
measurements [24]. In initial experiments, attempts
were made to blind investigators to the treatment group,
but these were ultimately unsuccessful due to myoclonus
and an obvious increase in sevoflurane requirement
observed in animals that received intrathecal strychnine.
In addition, though dizocilpine [25] and strychnine [26]
potently inhibit NMDA and glycine receptors, respect-
ively, their effects are not entirely limited to these recep-
tors. Both agents, for example, can modulate
acetylcholine receptors [27,28]. To the extent that these
or other non-specific receptor interactions contribute to
immobility [29], the MAC reduction attributed to
NMDA receptor inhibition could be overestimated. The
non-NMDA dizocilpine spinal effects, if present in this
study, should be similar between control and strychnine
rats; therefore the underlying conclusion that loss of gly-
cine receptor effects increases reliance on different
anesthetic-sensitive targets to achieve immobility at an
increased sevoflurane MAC remains valid.
Immobility may be produced by either anesthesia or
toxicity. Generally, anesthetic effects are reversible once
the drug is eliminated from the effect site, whereas toxic
effects are not. Both strychnine and dizocilpine can be
neurotoxic. Reversibility has been previously tested by
measuring baseline isoflurane MAC in rats, separately
administering strychnine or dizocilpine intrathecally,
and then recovering the rats and re-measuring baseline
isoflurane MAC two days later. At concentrations equal
to or higher than those used in the present study, strych-
nine and dizocilpine MAC-sparing effects were com-
pletely reversible [13,15]. Two other findings suggest
that our observations are not a result of toxicity. First,
variability between duplicate MAC measurements made
for each group and treatment was small. Had toxicity
occurred, then the second MAC measurement instead
should have been consistently and significantly lower
than the first due to progression of spinal injury from
continuous intrathecal drug administration. Second,
dizocilpine had a smaller sevoflurane MAC-sparing ef-
fect in rats receiving strychnine compared to control
animals (Figure 2). Had the combination of strychnine
and dizocilpine injured the spinal cord, then the exact
opposite result would have been expected.
At MAC, the magnitude of NMDA receptor modula-
tion by sevoflurane is increased when contributions of
other putatively relevant anesthetic targets to immobil-
ity, such as glycine receptors, are diminished. Mutability
of receptor contributions to prevent movement during
anesthesia is analogous to mutability of neuroanatomic
sites of action responsible for this same endpoint. Even
though immobility by volatile anesthetics is largely aspinal phenomenon, general anesthesia can nonetheless
be achieved when isoflurane is preferentially delivered to
the brain rather than the spinal cord, albeit at more than
twice the MAC as when the same agent is administered
systemically by inhalation [11]. Although isoflurane has
the capacity to produce anesthesia via supraspinal sites,
it does not for the reason that isoflurane can act at
spinal sites with high efficacy and greater potency to
cause immobility. Likewise, sevoflurane and other ether
anesthetics may be less efficacious NMDA receptor
antagonists at MAC for the very reason that they more
potently modulate other ion channels and receptors re-
sponsible for immobility during anesthesia.
Conclusion
Findings from this study suggest that the magnitude of
NMDA contributions to sevoflurane anesthesia may
therefore be determined indirectly by sevoflurane effi-
cacy and potency at other relevant cellular targets.
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